65490-08-6

Basic information

• Product Name: Ethanone, 1-[2-hydroxy-4-(methoxymethoxy)phenyl]-
• CAS NO: 65490-08-6
• Molecular Formula: C10H12O4
• Molecular Weight: 196.203
• Mol File: 65490-08-6.mol
• Article Data: 62

Chemical Properties

• CAS DataBase Reference: Ethanone, 1-[2-hydroxy-4-(methoxymethoxy)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-[2-hydroxy-4-(methoxymethoxy)phenyl]-(65490-08-6)
• EPA Substance Registry System: Ethanone, 1-[2-hydroxy-4-(methoxymethoxy)phenyl]-(65490-08-6)

Safety Data

• Hazardous Substances Data: 65490-08-6(Hazardous Substances Data)

Upstream product

• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 13057-17-5 bromethyl methyl ether 
• 109-87-5 Dimethoxymethane 
• 108-46-3 recorcinol 
• 107-30-2 chloromethyl methyl ether 
• 67-56-1 methanol 
• 130483-43-1 1-<2-hydroxy-4-(methoxymethoxy)phenyl>-3-phenylpropane-1,3-dione 

Downstream Products

• 109471-14-9 (2E)-1-[2-hydroxy-4-(methoxymethoxy)phenyl]-3-(4-methoxyphenyl)prop-2-en-1-one 
• 1072145-55-1 (+)-4'-tert-butyldimethylsilyloxy-2',7-(dibenzyloxy)isoflavan-3,4-diol 
• 57103-57-8 (+)-Glyceollin I 
• 62756-43-8 7-hydroxy-spiro<2H-1-benzopyran-2,1'-cyclohexane>-4(3H)-one 
• 70441-03-1 7-hydroxy-spiro<2H-1-benzopyran-2,1'-cyclopentane>-4(3H)-one 
• 1186018-78-9 3-(2,4-bis(methoxymethoxy)phenyl)-1-(2-hydroxy-4-(methoxymethoxy)-5-(3-methylbut-2-en-1-yl)phenyl)prop-2-en-1-one 
• 1186018-75-6 2,2',4,4'-tetrahydroxy-5-(3,3-dimethylallyl)chalcone 

Relevant articles and documents

New Seco-DSP derivatives as potent chemosensitizers

Thirty-four seco-3′R,4′R-disubstituted-2′,2′-dimethyldihydropyrano[2,3-f]chromone (seco-DSP) derivatives were designed, synthesized and evaluated for chemo-reversal activity when combined with paclitaxel or vincristine in P-gp overexpressing A2780/T and KB-VIN drug-resistant cancer cell lines. Most of the compounds displayed moderate to significant MDR reversal activities. Compound 7e showed the most potent chemo-sensitization activity with more than 1471 reversal ratio at a concentration of 10 μM, which was higher than verapamil (VRP) (212-fold). Unexpectedly the newly synthesized compounds did not show chemosensitization activities in a non-P-gp overexpressing cisplatin resistant human ovarian cancer cell line (A2780/CDDP), implying that the MDR reversal effects might be associated with P-gp overexpression. Moreover, the compounds did not exhibit significant anti-proliferative activities against non-tumorigenic cell lines (HUVEC, HOSEC and T29) compared to VRP at the tested concentration and might be safer than VRP. In preliminary pharmacological mechanism studies, the compounds increased accumulation of DOX and promoted P-gp ATPase activity in A2780/T cell lines. Western blot analysis indicated they did not affect the expression level of P-gp in the tested MDR cell lines. Thus, further studies on these seco-DSP derivatives are merited with the goal of developing a desirable chemosensitizer drug candidate.

Total Synthesis of the Natural Chalcone Lophirone E, Synthetic Studies toward Benzofuran and Indole-Based Analogues, and Investigation of Anti-Leishmanial Activity

The potential of natural and synthetic chalcones as therapeutic leads against different pathological conditions has been investigated for several years, and this class of compounds emerged as a privileged chemotype due to its interesting anti-inflammatory

Flavanone compound as well as preparation method and application thereof

The invention belongs to the technical field of medicines, and particularly relates to a flavanone compound as well as a preparation method and application thereof. Specifically disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound shown in the formula (I) can target hURAT1 and/or GLUT9, so that uric acid excretion is promoted, and the effect of reducing uric acid is achieved. The compound can be used for preparing medicines for treating and/or preventing and/or delaying and/or adjunctively treating and/or treating diseases related to hURAT1/GLUT9 activity, and has a good application prospect in preventing or treating diseases (such as gout, gouty arthritis, uric acid kidney stone and the like) related to hyperuricemia.

KRAS G12D INHIBITORS

The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.